专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009012958A3 TUBULYSIN D ANALOGUES 审中-公开
标题翻译：类毒素D类似物
公开(公告)号：WO2009012958A3
公开(公告)日：2009-04-23
申请号：PCT/EP2008005955
申请日：2008-07-21
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , ELLMAN JONATHAN A , PATTERSON ANDREW W , PELTIER HILLARY , SASSE FLORENZ
发明人： ELLMAN JONATHAN A , PATTERSON ANDREW W , PELTIER HILLARY , SASSE FLORENZ
IPC分类号： C07D277/56 , A61K38/08 , C07D417/12 , C07K5/02
CPC分类号： C07D277/56 , C07D417/12 , C07K5/06078
摘要： The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The essential features for the potent cytotoxicity of tubulysin D have been established for the first time by the synthesis and evaluation of a series of analogues. By identifying functionality that surprisingly is not necessary for activity, highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D.
摘要翻译：本发明提供了新的微管蛋白抑制剂类似物，制备这些类似物及其偶联物的方法和使用方法。第一次通过一系列类似物的合成和评估确定了微管相关蛋白D强效细胞毒性的基本特征。通过鉴定令人惊讶的对活性不必要的功能，已经开发了高度有效的细胞生长抑制剂，其比tubulysin D更小且更稳定。

2. 发明申请

WO2009013020A3 INHIBITOR OF THE MET-RECEPTOR AND ITS USE 审中-公开
标题翻译：金属受体的抑制剂及其用途
公开(公告)号：WO2009013020A3
公开(公告)日：2009-03-26
申请号：PCT/EP2008006200
申请日：2008-07-28
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , HEINZ DIRK , NIEMANN HARTMUT
发明人： HEINZ DIRK , NIEMANN HARTMUT
IPC分类号： C07K14/195 , C07K14/71 , G06F17/50 , G06F19/00 , G06F19/16 , G06F19/22
CPC分类号： G06F19/706 , C07K14/71 , C07K2299/00 , G06F19/16
摘要： The present invention relates to polypeptides being part of the Met-receptor forming a binding pocket allowing binding of inhibitors of the Met-receptor. In particular, the present invention relates to isolated and purified polypeptides consisting of a portion of the Met-receptor. In a further aspect, the present invention relates to the use of said polypeptide as a screening tool for an agent for treating or preventing cancer. Another aspect of the present invention relates to a method for identifying potential Met-receptor inhibitors based on the three-dimensional structure of the newly identified binding pocket for specific binding of inhibitors of the Met-receptor. Another aspect relates to the crystalline form of the Met-receptor molecule and its use for identifying potential inhibitor of the said receptor as well as inhibitor itself.
摘要翻译：本发明涉及作为形成结合口袋的Met受体的一部分的多肽，其允许与Met-受体的抑制剂结合。特别地，本发明涉及由部分Met-受体组成的分离和纯化的多肽。另一方面，本发明涉及所述多肽作为治疗或预防癌症的药物的筛选工具的用途。本发明的另一方面涉及一种基于新鉴定的结合口袋的三维结构鉴定潜在的Met-受体抑制剂的方法，用于特异性结合Met受体的抑制剂。另一方面涉及Met-受体分子的结晶形式及其用于鉴定所述受体的潜在抑制剂以及抑制剂本身的用途。

3. 发明申请

WO2008098787A3 CD83 AS A MOLECULAR SWITCH FOR THE INDUCTION OF REGULATORY (IMMUNOSUPPRESSIVE) T-CELLS 审中-公开
标题翻译： CD83作为诱导调控（免疫抑制）T细胞的分子开关
公开(公告)号：WO2008098787A3
公开(公告)日：2008-11-13
申请号：PCT/EP2008001186
申请日：2008-02-15
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , HANSEN WIEBKE , BUER JAN , REINWALD SIMONE
发明人： HANSEN WIEBKE , BUER JAN , REINWALD SIMONE
IPC分类号： G01N33/68
CPC分类号： G01N33/56972 , C07K14/70503 , G01N33/505 , G01N33/564 , G01N2333/70596 , G01N2500/00 , G01N2800/24
摘要： The present invention makes use of the role of the surface protein CD83 in the induction of regulatory T cells (Tregs). The present invention relates to means and methods for overexpressing CD83 as well as methods for identifying compounds that are interacting with the CD83 polypeptide, and to compounds capable of functioning as immunomodulators in mammals, in particular humans. In addition, the present invention relates to methods of treatment of a subject, in particular a human, suffering from an undesired immunoreaction. The transmembrane protein CD83 has been initially described as a maturation marker for dendritic cells (DCs). Moreover, there is increasing evidence that CD83 also regulates B cell function, thymic T cell maturation and peripheral T cell activation. Here, we show that CD83 expression confers immunosuppressive function to CD4 + T cells. CD83 mRNA is differentially expressed in naturally occurring CD4 + CD25 + regulatory T (Treg) cells and upon activation these cells rapidly express large amounts of surface CD83. Transduction of naive CD4 + CD25 - T cells with CD83 encoding retroviruses induces a regulatory phenotype in vitro, which is accompanied by the induction of Foxp3. Functional analysis of CD83-transduced T cells in vivo demonstrates that these CD83 + Foxp3 + T cells are able to interfere with the effector phase of severe contact hypersensitivity (CHS) reaction of the skin. Moreover, adoptive transfer of these cells prevents the paralysis associated with experimental autoimmune encephalomyelitis (EAE), suppresses pro-inflammatory cytokines IFN- and IL- 17 and increases anti-inflammatory IL-IO in recipient mice. Together, our data provides the first evidence that CD83 expression can contribute to the immunosuppressive function of CD4 + T cells in vivo.
摘要翻译：本发明利用表面蛋白CD83在诱导调节性T细胞（Treg）中的作用。本发明涉及用于过表达CD83的手段和方法以及用于鉴定与CD83多肽相互作用的化合物的方法，并且涉及能够在哺乳动物特别是人中用作免疫调节剂的化合物。另外，本发明涉及治疗患有不希望的免疫反应的受试者，特别是人的方法。跨膜蛋白CD83最初被描述为树突细胞（DC）的成熟标记。此外，越来越多的证据表明CD83还调节B细胞功能，胸腺T细胞成熟和外周T细胞活化。在这里，我们显示CD83表达赋予CD4 + + T细胞免疫抑制功能。 CD83 mRNA在天然存在的CD4 + / CD25 + /调节性T（Treg）细胞中差异性表达，并且在活化后，这些细胞迅速表达大量的表面CD83。原代CD4 + CD25 + T细胞与CD83编码逆转录病毒的转导在体外诱导调节表型，其伴随着Foxp3的诱导。体内CD83转导的T细胞的功能分析表明这些CD83 + Foxp3 + T细胞能够干扰严重接触过敏（CHS）反应的效应物阶段皮。此外，这些细胞的过继转移防止了与实验性自身免疫性脑脊髓炎（EAE）相关的麻痹，抑制了受体小鼠中的促炎细胞因子IFN-和IL-17并增加了抗炎IL-10。总之，我们的数据提供了CD83表达可以促进体内CD4 + / T细胞的免疫抑制功能的第一个证据。

4. 发明申请

WO2006094943A3 ACIDOPHILIC ENZYMES 审中-公开
标题翻译：醋酸酶
公开(公告)号：WO2006094943A3
公开(公告)日：2007-04-05
申请号：PCT/EP2006060450
申请日：2006-03-03
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , GOLYSHINA OLGA , GOLYSHINA PETER , TIMMIS KENNETH , FERRER MANUEL
发明人： GOLYSHINA OLGA , GOLYSHINA PETER , TIMMIS KENNETH , FERRER MANUEL
IPC分类号： C12N9/00 , C12N9/14 , C12N9/18 , C12N9/24
CPC分类号： C12N9/16 , C12N9/18 , C12N9/2402 , C12N9/93
摘要： The present invention relates to enzymes having catalytic activity at a pH below 5.0. The present invention provides hydrolyzing enzymes obtainable from archaeobacteria, in detail to hydrolytic enzymes obtainable from the archaeobacterium Ferroplasma acidiphilum. In general, the present invention provides enzymes which are active and stable at acidic pH values, especially at pH values from 1 to 4, especially in the range of pH 2 to 3, obtainable from Ferroplasma acidiphilum, especially to an esterase, glycosidases and a DNA ligase. In addition to stability and activity at low pH values, the enzymes according to the present invention are all dependent on Fe 2+ for their catalytic activity.
摘要翻译：本发明涉及在pH低于5.0时具有催化活性的酶。本发明提供了可从古细菌获得的水解酶，详细地可从碱性阿斯法氏球菌获得的水解酶。通常，本发明提供了在酸性pH值下，特别是在pH值为1至4，特别是在pH2至3的pH值范围内具有活性和稳定性的酶，其可从碳酸亚铁（Ferroplasma acidiphilum），特别是酯酶，糖苷酶和 DNA连接酶除了在低pH值下的稳定性和活性之外，根据本发明的酶对于其催化活性都依赖于Fe 2+ 2+。

5. 发明申请

WO2010130446A8 A METHOD FOR PRODUCING TEST SYSTEMS FROM DONORS SUFFERING FROM ADVERSE EFFECTS OF MEDICAMENTS AND/OR MEDICAL TREATMENTS, AND USES OF SAID SYSTEMS 审中-公开
标题翻译：从药物和/或医疗治疗的不良作用引起的捐助者生产测试系统的方法，以及用于系统的用途的方法
公开(公告)号：WO2010130446A8
公开(公告)日：2011-03-03
申请号：PCT/EP2010002940
申请日：2010-05-12
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , HANNOVER MED HOCHSCHULE , MAY TOBIAS , HAUSER HANSJOERG , WIRTH DAGMAR , CANTZ TOBIAS
发明人： MAY TOBIAS , HAUSER HANSJOERG , WIRTH DAGMAR , CANTZ TOBIAS
IPC分类号： C12N5/074
CPC分类号： C12N5/0672 , C12N5/0696 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2506/45 , C12N2510/00
摘要： The present invention relates to an in vitro method for producing induced stem cells (iSCs), in particular induced pluripotent stem (iPS) cells, derived from an mammal which suffers from at least one adverse effect caused by a medical treatment of a disease in said mammal, wherein said mammal has a genetic defect or genetic predisposition that is linked with said adverse effect against said medical treatment, comprising reprogramming of somatic cells obtained from said mammal with at least one suitable reprogramming factor. The present invention further relates to iSC-cell lines, preferably iPS-cell lines and their uses in screening methods in the context of searching for treatments lacking or having reduced side-effects.
摘要翻译：本发明涉及一种用于产生衍生自哺乳动物的诱导性干细胞（iSC）特别是诱导性多能干细胞（iPS）的体外方法，该哺乳动物患有由所述疾病的医学治疗引起的至少一种不良作用哺乳动物，其中所述哺乳动物具有与所述药物治疗的所述不利作用相关的遗传缺陷或遗传易感性，包括用至少一种合适的重新编程因子重新编程从所述哺乳动物获得的体细胞。本发明还涉及iSC-细胞系，优选iPS细胞系及其在筛选方法中在寻找缺乏或具有减少的副作用的治疗的上下文中的用途。

6. 发明申请

WO2008089831A3 G-PROTEIN COUPLED RECEPTOR 83 AS A MOLECULAR SWITCH FOR THE INDUCTION OF REGULATORY (IMMUNOSUPPRESSIVE) T-CELLS 审中-公开
标题翻译： G蛋白偶联受体83作为用于诱导调节（免疫抑制）T细胞的分子开关
公开(公告)号：WO2008089831A3
公开(公告)日：2008-09-12
申请号：PCT/EP2007011206
申请日：2007-12-19
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , HANSEN WIEBKE , BUER JAN
发明人： HANSEN WIEBKE , BUER JAN
IPC分类号： C07K14/72 , G01N33/50 , G01N33/74
CPC分类号： C07K14/705 , G01N33/5008 , G01N33/505 , G01N33/566 , G01N33/74 , G01N2333/726
摘要： The present invention makes use of the role of the G-protein coupled receptor 83 (GPCR83) in the induction of regulatory T cells (Tregs) during the course of ongoing immune response. The present invention relates to means and methods for identifying compounds that are interacting with the GPCR83 polypeptide, and to compounds capable of functioning as immunomodulators in mammals, in particular humans. In addition, the present invention relates to methods of treatment of a subject, in particular a human, suffering from an undesired immunoreaction.
摘要翻译：本发明利用G蛋白偶联受体83（GPCR83）在持续免疫反应过程中诱导调节性T细胞（Treg）的作用。本发明涉及用于鉴定与GPCR83多肽相互作用的化合物的方法和方法，以及能够在哺乳动物，特别是人中作为免疫调节剂起作用的化合物。此外，本发明涉及治疗患有不想要的免疫反应的受试者，特别是人的方法。

7. 发明申请

WO2007054283A2 PQS AND ITS CONJUGATES AS ADJUVANTS AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译： PQS及其作为补充剂及其在药物组合物中的应用
公开(公告)号：WO2007054283A2
公开(公告)日：2007-05-18
申请号：PCT/EP2006010699
申请日：2006-11-08
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , EBENSEN THOMAS , MORR MICHAEL , GUZMAN CARLOS A
发明人： EBENSEN THOMAS , MORR MICHAEL , GUZMAN CARLOS A
CPC分类号： A61K39/39 , A61K31/7076 , A61K31/7084 , A61K2039/55511
摘要： The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
摘要翻译：本发明涉及新的佐剂和药物组合物中的用途，如疫苗。特别地，本发明提供了新的化合物，其可用作用于治疗感染性疾病，炎性疾病，自身免疫性疾病，肿瘤，过敏症以及用于控制人的生育能力的预防和/或治疗性疫苗的佐剂和/或免疫调节剂动物种群。所述化合物不仅特别适用于全身，而且优选作为粘膜佐剂。此外，本发明涉及其作为药物组合物中的活性成分的用途。

8. 发明申请

WO2011012311A8 METHODS AND TESTS FOR SCREENING BACTERIAL BIOFILMS 审中-公开
标题翻译：筛选细菌生物膜的方法和试验
公开(公告)号：WO2011012311A8
公开(公告)日：2012-04-05
申请号：PCT/EP2010004670
申请日：2010-07-30
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , MUESKEN MATHIAS , HAEUSSLER SUSANNE
发明人： MUESKEN MATHIAS , HAEUSSLER SUSANNE
IPC分类号： C12Q1/18 , C12R1/385
CPC分类号： C12Q1/18 , C12Q1/04 , G01N2800/52
摘要： In a first aspect, the present invention relates to a method for screening bacteria on their susceptibility against candidate compounds. In a further aspect, the present invention relates to a method for screening the antibiotic efficacy of candidate compounds suppose to have an antibiotic activity on bacteria. Moreover, the present invention relates to a method for forming a bacterial biofilm on a support, a system allowing in vitro and in vivo evaluation of biofilms formed by bacteria as well as methods for the stratification of the treatment regimen against bacterial infections.
摘要翻译：在第一方面，本发明涉及一种筛选细菌对其候选化合物敏感性的方法。在另一方面，本发明涉及一种筛选候选化合物的抗生素功效的方法，假定对细菌具有抗生素活性。此外，本发明涉及在载体上形成细菌生物膜的方法，允许体外和体内评估由细菌形成的生物膜的系统以及用于分层治疗方案对细菌感染的方法。

9. 发明申请

WO2011012720A3 COMPOSITIONS FOR GENERATING AN ANTIGEN SPECIFIC IMMUNE RESPONSE 审中-公开
标题翻译：产生抗原特异性免疫应答的组合物
公开(公告)号：WO2011012720A3
公开(公告)日：2011-12-22
申请号：PCT/EP2010061161
申请日：2010-07-30
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , ZENDER LARS
发明人： ZENDER LARS
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K31/00 , A61K35/12 , A61K2039/5152 , C12N5/0693
摘要： The present invention provides for the purposeful utilisation of the induction of senescence in eukaryotic cells for induction of an antigen specific immune response. Such cells can be normal cells, pre-malignant and malignant cells as well as virally or bacterially infected cells, for the generation of an immune response, preferably a cellular or humoral immune response comprising T-cells and/or B-cells, whose immune response is directed specifically against antigens from those cells in which senescence was induced and then comprises an immune response against the senescent cells itself as well as to the non-senescent counterparts harbouring the same antigens.
摘要翻译：本发明提供了有目的的利用诱导衰老的真核细胞诱导抗原特异性免疫应答。这样的细胞可以是正常细胞，恶变前和恶性细胞以及病毒或细菌感染的细胞，用于产生免疫应答，优选包含T细胞和/或B细胞的细胞或体液免疫应答，其免疫反应特别针对来自诱导衰老的那些细胞的抗原，然后包含针对衰老细胞本身以及具有相同抗原的非衰老对应物的免疫应答。

10. 发明申请

WO2010136580A3 TUMOUR-SPECIFIC BACTERIAL PROMOTER ELEMENTS 审中-公开
标题翻译：肿瘤特异性细菌促进因子
公开(公告)号：WO2010136580A3
公开(公告)日：2011-03-31
申请号：PCT/EP2010057452
申请日：2010-05-28
申请人： HELMHOLTZ INFEKTIONSFORSCHUNG , WEISS SIEGFRIED , BARTELS SARA , LOESSNER HOLGER , DEYNEKO IGOR , BUMANN DIRK , WESTPHAL-DANIEL KATHRIN
发明人： WEISS SIEGFRIED , BARTELS SARA , LOESSNER HOLGER , DEYNEKO IGOR , BUMANN DIRK , WESTPHAL-DANIEL KATHRIN
IPC分类号： C12N15/09 , A61K48/00 , C12N15/85
CPC分类号： A61K48/0058 , C12N15/1051 , C12N15/1086 , C12N15/70 , C12N15/85 , C12N2830/008
摘要： The invention relates to bacterial promoter elements which constitute or which are comprised in promoter regions and which confer tumour specificity to the promoter region activity, resulting in transcription of a transgene, which can be a heterologous or a homologous gene, which transgene is functionally arranged downstream of the promoter region at presence of a host bacterium in tumour tissue, while essentially conferring inactivity of the promoter region and no transcription at presence of the host bacterium in non-tumour tissue. Accordingly, the invention relates to bacterial promoter regions containing these tumour specific promoter elements.
摘要翻译：本发明涉及构成或包含在启动子区中并且赋予启动子区活性的肿瘤特异性的细菌启动子元件，导致可以是异源或同源基因的转基因的转录，转基因功能上被布置在下游在肿瘤组织中宿主细菌存在下的启动子区域，而基本上赋予启动子区域的不活动并且在非肿瘤组织中存在宿主细菌时没有转录。因此，本发明涉及含有这些肿瘤特异性启动子元件的细菌启动子区域。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式